00:05 , Aug 9, 2019 |  BC Innovations  |  Tools & Techniques

The next frontier for single-cell analysis

With an explosion in scalability, single-cell analysis has begun to invade every aspect of drug development, with early benefits showing themselves in precision targeting. The field’s next challenge is to integrate a wider array of...
23:14 , Apr 11, 2019 |  BC Innovations  |  Targets & Mechanisms

A venture view of biological white space

Scanning the horizon of translational research, VCs on BioCentury’s scientific advisory board see innate neuroinflammation as a white space area flush with under-tapped angles for drug development, and think the rise of single cell-level data...
19:47 , Mar 19, 2019 |  BC Extra  |  Tools & Techniques

FNIH launches project to improve TB vaccination

Backed by the Bill & Melinda Gates Foundation, the Foundation for the National Institutes of Health launched a project to study a new delivery route to improve the efficacy of the only approved tuberculosis vaccine....
19:27 , Sep 28, 2018 |  BC Week In Review  |  Company News

Agilent acquires tools company Acea to expand China footprint

Agilent Technologies Inc. (NYSE:A) acquired cell analysis tools company Acea Biosciences Inc. (San Diego, Calif.) for $250 million. Agilent said the acquisition will expand the company's capabilities in China, where Acea has a large manufacturing...
23:48 , Sep 14, 2018 |  BioCentury  |  Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
00:55 , Jun 23, 2018 |  BioCentury  |  Emerging Company Profile

Cerevance’s human element

Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will...
23:52 , Mar 6, 2018 |  BC Extra  |  Preclinical News

FNIH reviews single-cell analysis landscape

A review of single-cell analysis tools highlights six new technologies with translational potential and examines the primary hurdles for broader utilization -- heterogeneity and variability. The review was published on March 2 in Clinical and...
16:29 , Aug 18, 2017 |  BC Week In Review  |  Financial News

Atreca raises $35M in series B

On Aug. 17, cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing...
19:03 , Aug 17, 2017 |  BC Extra  |  Financial News

Atreca raises $35M in series B

Cancer immunotherapy company Atreca Inc. (Redwood City, Calif.) raised $35 million in a series B round co-led by new investor Wellington Management and an undisclosed U.S. healthcare fund, which is an existing investor. New investor...
19:10 , Jun 23, 2017 |  BC Week In Review  |  Company News

University of Maryland grants Cellth license for circulating tumor cell analysis

University of Maryland (College Park, Md.) granted Cellth Systems LLC (Annapolis, Md.) exclusive rights to cell-tethering technology that allows for analysis of circulating tumor cells. The technology can quantify changes in circulating tumor cells in...